TITLE

tobramycin

PUB. DATE
January 2002
SOURCE
Royal Society of Medicine: Medicines;2002, p538
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
This article provides information on tobramycin, an antibacterial and antibiotic drug of the aminoglycoside group. The drug is effective against some Gram-positive and Gram-negative bacteria and is used primarily for the treatment of serious Gram-negative infections caused by Pseudomonas aeruginosa, because it is significantly more active against this organism than gentamicin. Like other aminoglycosides, it is not absorbed from the intestine and so is administered by injection or intravenous infusion. It is also available as eye-drops to treat bacterial infections of the eye.
ACCESSION #
18961877

 

Related Articles

  • Tobi.  // Royal Society of Medicine: Medicines;2002, p538 

    This article provides information on Tobi, a proprietary, prescription-only preparation of the antibacterial and antibiotic tobramycin. The drug can be used to treat serious bacterial infections, particularly Pseudomonas aeruginosa infection in cystic fibrosis patients over six years. It is is...

  • Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. Alipour, Misagh; Suntres, Zacharias E.; Omri, Abdelwahab // Journal of Antimicrobial Chemotherapy (JAC);Aug2009, Vol. 64 Issue 2, p317 

    Objectives This study evaluated the potential of DNase, alginate lyase (AlgL) and N-acetylcysteine (NAC) in enhancing the in vitro bactericidal activity of conventional (free) and vesicle-entrapped (liposomal) gentamicin, amikacin and tobramycin. Methods The MICs and biofilm eradication for two...

  • piperacillin.  // Royal Society of Medicine: Medicines;2002, p441 

    The article presents information on piperacillin which is a broad spectrum antibacterial and antibiotic that is used to treat many serious or compound forms of bacterial infection, particularly those caused by Pseudomonas aeruginosa, and in prophylaxis after surgery. Administration is by...

  • Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis. Adis International Limited // Drugs & Therapy Perspectives;Sep2004, Vol. 20 Issue 9, p1 

    Focuses on the effects of inhaled tobramycin on lung function and bacterial density associated with Pseudomonas aeruginosa infections in cystic fibrosis patients. Clinical benefits and potential limitations of tobramycin solution for inhalation (TSI) in the management of Pseudomonas aeruginosa...

  • Tobramycin.  // Reactions Weekly;11/18/2006, Issue 1128, p18 

    The article presents the case of an older woman who developed acute renal failure during treatment with inhaled tobramycin. The patient was hospitalised for decreased urine output and sepsis secondary to Pseudomonas aeruginosa. The findings from a urine sediment examination are described....

  • Current Treatment of Pseudomonal Infections in the Elderly. Pappas, Georgios; Saplaoura, Kaiti; Falagas, Matthew E. // Drugs & Aging;2009, Vol. 26 Issue 5, p363 

    Pseudomonas aeruginosa infections have emerged as a major infectious disease threat in recent decades as a result of the significant mortality of pseudomonal pneumonia and bacteraemia, and the evolving resistance exhibited by the pathogen to numerous antibacterials. Pseudomonas possesses a large...

  • An usual approach to treatment of a case of multidrug resistance Pseudomonas aeruginosa peritonitis: parenteral and intraperitoneal aminoglycosides and parenteral colistin. May, Ian; Abu-Khdeir, Maha; Blackwood, Roland Alexander // Infectious Disease Reports;2012, Vol. 4 Issue 2, p142 

    Infections caused by Pseudomonas aeruginosa are becoming more common and increasingly more difficult to treat due to the continued development of drug resistance. While sensitivity to colistin (polymyxin E) is well known, it is frequently avoided due to concerns of nephrotoxicity. Reported here...

  • Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Askoura, Momen; Mottawea, Walid; Abujamel, Turki; Taher, Ibrahim // Libyan Journal of Medicine;Sep2011, Vol. 6 Issue 6, p1 

    Pseudomonas aeruginosa is an opportunistic human pathogen and one of the leading causes of nosocomial infections worldwide. The difficulty in treatment of pseudomonas infections arises from being multidrug resistant (MDR) and exhibits resistance to most antimicrobial agents due to the expression...

  • Honey as an Antimicrobial Agent Against Pseudomonas Aeruginosa Isolated from Infected Wounds. Shenoy, Vishnu Prasad; Ballal, Mamatha; Shivananda, P. G.; Bairy, Indira // Journal of Global Infectious Diseases;Apr2012, Vol. 4 Issue 2, p102 

    Background: As natural products garner attention in the medical field due to emergence of antibiotic resistant strains of bacteria, honey is valued for its antibacterial activity. Objective: Fifty strains of Pseudomonas aeruginosa isolated from infected wounds were evaluated for their...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics